Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K
16 Março 2021 - 9:18PM
Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today
announces that it has filed its annual report on Form 10-K for the
year ended December 31, 2020 with the U.S. Securities and Exchange
Commission. A copy of the annual report is available on Intec’s
website, www.intecpharma.com, by selecting “Investors” and then
“Financials” and “SEC Filings”.
You may request a copy of the Company’s Form 10-K, at no cost to
you, by writing to the Chief Financial Officer of the Company at 12
Hartom Street, Har Hotzvim, Jerusalem 9777512, Israel or by calling
the Company at +972 (2) 586 4657.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage
biopharmaceutical company focused on developing drugs based on its
proprietary Accordion Pill platform technology. The Company's
Accordion Pill is an oral drug delivery system that is designed to
improve the efficacy and safety of existing drugs and drugs in
development by utilizing an efficient gastric retention and
specific release mechanism. For more information,
visit www.intecpharma.com. Intec Pharma routinely
posts information that may be important to investors in the
Investor Relations section of its website.
No Offer or Solicitation
This communication shall not constitute an offer
to sell or the solicitation of an offer to buy any securities, nor
shall there be any sale of securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction. No offering of securities shall be made except by
means of a prospectus meeting the requirements of Section 10 of the
Securities Act.
Additional Information about the Proposed Merger and Where to
Find It
In connection with the proposed merger between
Intec Pharma and Decoy Biosystems, Intec Pharma will file a
Registration Statement on Form S-4, which will include a document
that serves as a proxy statement and prospectus of Intec Pharma and
Intec Pharma plans to file other documents regarding the proposed
merger with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO
READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS
FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY
BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
THAT SHAREHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION
REGARDING THE PROPOSED MERGER. A definitive proxy
statement/prospectus will be sent to Intec Pharma’s and Decoy
Biosystems’ shareholders. Investors and security holders will be
able to obtain these documents (when available) free of charge from
the SEC’s website at www.sec.gov. The documents filed by Intec with
the SEC may also be obtained free of charge from the Company by
requesting them by mail at Intec Pharma Ltd., 12 Hartom Street, Har
Hotzvim, Jerusalem 9777512, Israel.
Participants in the Solicitation
Intec Pharma and its respective directors and
executive officers and other members of management and employees
and certain of their respective significant shareholders may be
deemed to be participants in the solicitation of proxies from Intec
shareholders in respect of the proposed merger. Information about
the Intec Pharma’s directors and executive officers is available in
Intec’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2020, which was filed with the SEC on March 16, 2021.
Information regarding the persons who may, under the rules of the
SEC, be deemed participants in the proxy solicitation and a
description of their direct and indirect interests, by security
holding or otherwise, will be contained in the proxy
statement/prospectus and other relevant materials to be filed with
the SEC regarding the proposed merger when they become available.
Investors should read the proxy statement/prospectus carefully when
it becomes available before making any voting or investment
decisions. You may obtain free copies of these documents from the
SEC and Intec Pharma as indicated above.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking
statements with the meaning of the Private Securities Litigation
Reform Act. These include statements regarding management’s
expectations, beliefs and intentions regarding, among other things,
our product development efforts, business, financial condition,
results of operations, strategies, plans and prospects.
Forward-looking statements can be identified by the use of
forward-looking words such as “believe”, “expect”, “intend”,
“plan“, “may“, “should“, “could“, “might“, “seek“, “target“,
“will”, “project“, “forecast“, “continue” or “anticipate” or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. For example, forward-looking statements are
used in this press release when we discuss Decoy’s future plans and
expected timeline of its development pipeline and our expected
timing of completion of the merger. Forward-looking statements
relate to anticipated or expected events, activities, trends or
results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that
could cause our actual results to differ materially from any future
results expressed or implied by the forward-looking statements.
Many factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: risks associated with Intec Pharma’s and Decoy’s ability
to obtain the shareholder approval required to consummate the
proposed merger and the timing of the closing of the proposed
merger, including the risks that a condition to closing would not
be satisfied within the expected timeframe or at all or that the
closing of the proposed merger will not occur; risks related to the
ability to consummate certain closing conditions including the
pre-closing financing and the disposition of the Accordion Pill
business, the occurrence of any event, change, or other
circumstances that could give rise to the termination of the merger
agreement; the outcome of any legal proceedings that may be
instituted against Intec Pharma or Decoy following the announcement
of the merger agreement and the transactions contemplated therein;
unanticipated difficulties or expenditures relating to the proposed
merger, the response of business partners and competitors to the
announcement of the proposed merger, and/or potential difficulties
in employee retention as a result of the announcement and pendency
of the proposed merger; the occurrence of any event, change, or
other circumstance that could give rise to the termination of the
merger agreement or could otherwise cause the transaction to fail
to close; the inability to list the merger shares on Nasdaq or
maintain the listing of the combined company’s shares of common
stock on Nasdaq following the proposed merger; the ability to
recognize the anticipated benefits of the proposed merger. Risks
and uncertainties relating to Decoy that may cause actual results
to differ materially from those expressed or implied in any
forward-looking statement include, but not limited to: Decoy’s
plans to develop and potentially commercialize its technology, the
timing and cost of Decoy’s planned investigational new drug
application and any clinical trials, the completion and receiving
favorable results in any clinical trials, Decoy’s ability to obtain
and maintain regulatory approval of any product candidate, Decoy’s
ability to protect and maintain its intellectual property and
licensing arrangements, Decoy’s ability to develop, manufacture and
commercialize its product candidates, the risk of product liability
claims, the availability of reimbursement, the influence of
extensive and costly government regulation, and Decoy’s estimates
regarding future revenue, expenses capital requirements and the
need for additional financing following the merger. These risks, as
well as other risks and uncertainties associated with the merger,
will be discussed in the proxy statement/prospectus that will be
included in the registration statement on Form S-4 to be filed with
the SEC in connection with the merger. Additional risks and
uncertainties are identified and discussed under the heading “Risk
Factors” in Intec’s Annual Report and other period filings with the
SEC. All forward-looking statements speak only as of the date of
this presentation and are expressly qualified in their entirety by
the cautionary statements included in this presentation. Neither
Intec nor Decoy undertake any obligation to update or revise
forward-looking statements to reflect events or circumstances that
arise after the date made or to reflect the occurrence of
unanticipated events, except as required by applicable law.
Intec Pharma Investor Contact:Will O'Connor
Stern IR +1 212-362-1200
will@sternir.com
Intec Parent (NASDAQ:NTEC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Intec Parent (NASDAQ:NTEC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024